Faida
User from
simple but informative
Posted on 27/05/2026
Carcinoma in-situ of the Breast is a Continuing Professional Development (CPD) course designed to provide healthcare professionals with an evidence-based understanding of non-invasive breast cancer conditions, including Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The course explores the pathology, diagnosis, imaging, biopsy techniques, treatment pathways, patient counselling, and evolving management approaches for carcinoma in-situ of the breast. Breast carcinoma in-situ refers to abnormal cells confined within the ducts or lobules of the breast without invasion into surrounding breast tissue. While these conditions are considered non-invasive, early recognition and appropriate management are important to reduce progression risk and improve patient outcomes.
.jpg)
Stay updated with our


Stay updated with our


.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
User from
simple but informative
Posted on 27/05/2026
Join Care Learning as a trainer and deliver high-quality courses to learners across healthcare and workplace training.
Invite healthcare professionals to join Care Learning and get rewarded when your referral successfully joins.
It is a non-invasive breast condition where abnormal cells remain confined within the ducts or lobules.
DCIS occurs in the ducts and may progress to invasive cancer, while LCIS develops in the lobules and mainly indicates increased breast cancer risk.
How is carcinoma in-situ detected? It is commonly detected through breast screening mammography and confirmed with biopsy.
Mammography, ultrasound, and breast MRI may be used depending on clinical circumstances.
Selected low-risk patients may be suitable for surveillance under specialist supervision.
Multidisciplinary teams help ensure accurate diagnosis, treatment planning, and patient-centred care.